

**Supplementary Table 1. Summary of patients' characteristics and treatment details**

Patient no.	Age, yr	Sex	Tumor grade	Metastatic sites	Previous treatment	Ki-67 index, %	Cycles of CAPTEM	Temozolomide dose, mg	Capcitabine dose, mg	Best response	OS, mo	PFS, mo
1	42	Female	NET, grade2	Liver	-	3	46	300	1,000	PR	65.3	54.17
2	59	Male	NET, grade2	Liver	-	8	2	300	1,150	SD	44.5	44.5
3	38	Male	NET, grade2	Liver, lymph node	-	12	5	300	1,150	SD	8.97	3.57
4	66	Female	NET, grade2	Liver	Surgery	6.76	7	300	1,000	PR	7.07	7.07
5	49	Female	NET, grade2	Liver, lymph node	-	4	10	300	1,150	SD	41.17	10.47
6	72	Male	NET, grade2	Liver, lymph node, mediastinum	-	5	25	300	1,150	SD	41.43	39.7
7	63	Male	NET, grade3	Liver	Surgery, TACE	40	3	300	1,150	PD	31.47	2.37
8	74	Female	NET, grade3	Lymph node, bone	Chemotherapy (EP, IP)	88.5	2	300	1,300	PD	15.87	2.77
9	60	Female	NET, grade3	Liver	Surgery	30	21	300	1,150	PR	23.73	23.73
10	51	Female	NEC	Liver, lymph node	Surgery, chemotherapy (EP, IP)	90	5	350	1,300	PR	11.2	4.6
11	69	Female	NEC	Liver, lymph node, adrenal gland	Chemotherapy (EP, IP)	80	2	300	1,500	PD	3.23	2.07
12	67	Male	NEC	Liver, lymph node, peritoneum	Surgery, chemotherapy (EP)	40	4	370	1,300	SD	5.47	3.73

CAPTEM, capecitabine and temozolomide; OS, overall survival; PFS, progression-free survival; NET, neuroendocrine tumor; PR, partial response; SD, stable disease; TACE, transarterial chemoembolization; PD, progressive disease; EP, etoposide+ cisplatin chemotherapy; IP, irinotecan+ cisplatin chemotherapy; NEC, neuroendocrine carcinoma.